Fennec Pharmaceuticals, Inc. (FENC)
12.76
+1.14
(+9.81%)
USD |
NASDAQ |
Nov 16, 16:00
12.58
-0.18
(-1.41%)
After-Hours: 20:00
Fennec Pharmaceuticals Gross Profit Margin (Quarterly) : 95.73% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 95.73% |
| June 30, 2026 | 95.97% |
| March 31, 2026 | 96.23% |
| December 31, 2025 | 87.20% |
| September 30, 2025 | 94.70% |
| June 30, 2025 | 89.98% |
| March 31, 2025 | 95.74% |
| December 31, 2024 | 91.56% |
| September 30, 2024 | 80.54% |
| June 30, 2024 | 91.63% |
| March 31, 2024 | 97.83% |
| December 31, 2023 | 92.96% |
| Date | Value |
|---|---|
| September 30, 2023 | 94.92% |
| June 30, 2023 | 95.55% |
| March 31, 2023 | 94.34% |
| December 31, 2022 | 94.40% |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 89.75% |
| Alnylam Pharmaceuticals, Inc. | 75.19% |
| Anika Therapeutics, Inc. | 61.57% |
| Savara, Inc. | -- |
| Arrowhead Pharmaceuticals, Inc. | 76.64% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 5.21% |
| Return on Assets | 2.38% |
| Return on Invested Capital | 4.68% |
| Profit Margin (Quarterly) | 23.66% |
| Operating Margin (Quarterly) | 23.74% |
| Return on Net Operating Assets | 5.08% |